Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis最新文献

{"title":"Interpretability of the Quantra viscoelastic test in patients with haematological malignancies presenting severe thrombocytopenia.","authors":"Adrien Contejean, Florence Blanc-Jouvan, Noémie Zucman, Claire Reynes, Yacine Haddad, Cloe Derray, Constance Moulinier, Natacha Mauz, Nicolas Daguindau, Marion Chevalier, Stéphanie Tardy, Frédérique Orsini-Piocelle, Anne Parry, Hannah Moatti, Albrice Levrat, Tristan Delory","doi":"10.1097/MBC.0000000000001462","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001462","url":null,"abstract":"<p><p>Viscoelastic tests have been scarcely evaluated in patients with haematological malignancies and severe thrombocytopenia. The VISCOTHEM-1 study investigated the interpretability of Quantra results in these patients, with platelet count less than 50 × 109/l. The objective was to evaluate the correlation between clot stiffness and platelet contribution to clot stiffness (PCS) measured by Quantra and conventional laboratory platelet counts. In this exploratory, single-centre, nonrandomized prospective cohort (June-December 2024), adults with haematological malignancies, platelet count less than 50 × 109/l and no antiplatelet/anticoagulant therapy or platelet-function disorders were enrolled. Patients underwent a blood count, coagulation assays, Quantra and ROTEM assessments. For patients who received transfusion, a second draw was performed one hour posttransfusion. Forty-six patients were included: 16 with platelet counts less than 10 × 109/l, 15 between 10 and 19 × 109/l, and 15 between 20 and 49 × 109/l. Fourteen patients (31%) experienced bleeding. The median PCS measured by Quantra was 2 hPa [interquartile range (IQR) 2-3.38] and correlated strongly with platelet count using conventional assay (r = 0.84, P < 0.05) and with MCE platelets measured by ROTEM (r = 0.78, P < 0.05). Clot stiffness was moderately correlated with platelet count (r = 0.48, P < 0.05) and strongly with MCF-EXTEM (r = 0.79, P < 0.05). The range of PCS values differentiated most patients except in the less than 10 × 109/l subgroup. The distributions of clot stiffness, clotting time and fibrinogen contribution to clot stiffness measured by Quantra reliably discriminated between all patients regardless of platelet count. After transfusion, PCS and clot stiffness increased significantly. Quantra results were interpretable in patients with haematological malignancies and platelet counts below 50 × 109/l and correlated both with ROTEM parameters and with conventional haemostasis assays.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149280553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroid-associated hypofibrinogenemia: an overlooked risk in graft-versus-host disease management after allogeneic hematopoietic stem cell transplantation.","authors":"Fahir Ozturk, Gulten Korkmaz, Merve Ecem Erdogan Yon, Funda Ceran, Simten Dagdas, Gulsum Ozet","doi":"10.1097/MBC.0000000000001460","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001460","url":null,"abstract":"<p><p>Steroid-associated hypofibrinogenemia represents a rare but clinically significant complication in patients receiving systemic corticosteroids for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We report a case of steroid-associated hypofibrinogenemia in a 47-year-old woman with acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Treatment with methylprednisolone (1 mg/kg/day) for late acute gastrointestinal graft-versus-host disease resulted in severe fibrinogen depletion from 3.44 g/l to a nadir of 0.35 g/l within 19 days, without progressive laboratory findings suggestive of disseminated intravascular coagulation or hepatic synthetic dysfunction. Disseminated intravascular coagulation (DIC) and hepatic dysfunction were not supported by the clinical, laboratory, and imaging findings. No major bleeding occurred despite profound hypofibrinogenemia. Following steroid discontinuation, fibrinogen levels recovered rapidly, reaching 1.55 g/l at day 38 postcessation. This case highlights steroid-associated hypofibrinogenemia as an underrecognized but clinically important coagulation disorder that requires monitoring in patients receiving high-dose corticosteroids.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149280562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical burden of haemophilia in Abu Dhabi, United Arab Emirates: real-world insights from the Malaffi platform.","authors":"Muna Alsafi, Alia Aldhaheri, Subhashini Ganesan, Flavia Martinez Cantarutti, Hannah V Wilson, Kate Dudek, Islam Eltantawy, Thekra Mohamed, Shahrukh Hashmi, Asma AlMannaei","doi":"10.1097/MBC.0000000000001474","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001474","url":null,"abstract":"<p><p>This study aims to understand the clinical burden of haemophilia by assessing the real-world patient profile, treatment, and healthcare utilization of people with haemophilia (PwH) in Abu Dhabi. A retrospective observational study was conducted using electronic health records from the Malaffi database (patient health information platform). Patients with a diagnosis of haemophilia A (ICD-10 D66) or haemophilia B (ICD-10 D67) between 1 January 2021, and 14 April 2023, and with documented haemophilia-related treatment, were included. Demographic characteristics, clinical presentation, comorbidities, treatment patterns, and healthcare encounters were analysed using descriptive statistics. A total of 146 PwH were identified, 83% (n = 121) presented with haemophilia A. Paediatric patients comprised 65% (n = 95) with mean age 6.3 ± 5.6 years and adults 35% (n = 51) with average age of 30.4 ± 10.1 years. Pain and swelling were the most common symptoms documented in both groups (77% paediatric; 88% adult). The most frequently identified comorbid conditions include joint/arthritic conditions among adults (75%) and anaemia among the paediatric patients (61%). PwH recorded 6052 healthcare encounters during the study period with a median of 10 visits per PwH per year. The ordered medications included 1422 prescriptions, and factor VIII (862 prescriptions) was the most prescribed medication. The study provides robust evidence on the clinical burden and intense utilization of healthcare resource of PwH in Abu Dhabi and offer foundation for future research and policy initiatives aimed at optimizing care delivery and resource allocation for PwH.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149280635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous hematopoietic stem cell transplantation in a patient with relapsed diffuse large B-cell lymphoma and type 3 von Willebrand disease: a case report.","authors":"Saša Anžej Doma, Matija Rozman, Martina Fink, Irena Preložnik Zupan","doi":"10.1097/MBC.0000000000001465","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001465","url":null,"abstract":"<p><p>Autologous hematopoietic stem cell transplantation (auto-HSCT) is standard therapy for eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Type 3 von Willebrand disease (VWD) poses additional haemostatic challenges during postconditioning aplasia. We report a 65-year-old man with DLBCL in second complete remission and type 3 VWD who underwent auto-HSCT. During bone marrow aplasia, complicated by mucositis and melena, intensified VWF/FVIII replacement and transfusion support were required. Following a switch to a concentrate with a higher VWF-to-FVIII ratio, improved haemostatic control was achieved. Poor platelet increments were associated with anti-HLA class I antibodies, indicating immune-mediated platelet refractoriness. Bleeding was controlled with twice-daily platelet transfusions, full-dose antifibrinolytic therapy, and VWF/FVIII replacement maintaining trough levels above 0.50 IU/ml. To our knowledge, this is the first reported case of auto-HSCT in a patient with a severe congenital bleeding disorder, highlighting the importance of individualized VWF/FVIII replacement and optimized transfusion support.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of the monitoring of argatroban by anti-IIa methods, ecarin assays, point-of-care testing methods and specialized drug quantification methods for patients with heparin-induced thrombocytopenia.","authors":"Susan Guy, Kevin Horner, Kerensa Leeson, Rhona Maclean","doi":"10.1097/MBC.0000000000001470","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001470","url":null,"abstract":"<p><p>Heparin-induced thrombocytopenia (HIT) is caused by anti-PF4/heparin IgG antibodies stimulating platelet activation, causing thrombocytopenia and thrombosis. Classical HIT occurs due to exposure to heparin, whereas autoimmune HIT occurs via heparin-independent platelet activation (caused by anti-PF4/polyanion IgG) and relates to a platelet count fall that begins or persists without heparin. Treatment for HIT requires transitioning patients onto alternative anticoagulation. The direct thrombin inhibitor argatroban has been licensed for use in patients with HIT and was recommended to be monitored by the activated partial thromboplastin time (aPTT). Recent European guidelines have suggested that monitoring drug concentrations is more suitable and will reduce the risk of under or over anticoagulating patients. This review will discuss anti-IIa and ecarin-based laboratory methods for determining plasma argatroban concentrations, the use of viscoelastography methods and other point-of-care testing (POCT) methods in whole blood. The use of more specialised tests based on high-performance liquid chromatography will also be discussed, comparing these methods with aPTT.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the relationship between age and gender of blood donors with oxidative stress, and mitochondrial DNA release in platelet concentrates during storage.","authors":"Fatemeh Nakhaei Moghaddam, Shahram Samiee, Amir Teimourpour, Mohammad Reza Deyhim","doi":"10.1097/MBC.0000000000001461","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001461","url":null,"abstract":"<p><p>The variations in donor characteristics, may affect the progression of platelet storage lesion (PSL). Additionally, oxidative conditions and mitochondrial function play a role in these alterations. This study aims to investigate the impact of donor age and gender on oxidative stress and mitochondrial DNA (mtDNA) during the storage of platelet concentrates. In this study, 42 platelet-rich plasma platelet concentrates (PRP-PCs) were selected from male and female donors. We measured the research parameters, which include; platelet count, platelet metabolism, oxidative parameters, platelet viability and mtDNA during platelet concentrate storage. We found a significant increase in the levels of reactive oxygen species (ROS) and malondialdehyde (MDA), along with a decrease in pH, in platelet concentrates obtained from female in comparison to male blood donors (P < 0.05). Correlation analysis indicated a direct relationship between mtDNA and both ROS and MDA, as well as a negative correlation between mtDNA and pH. These alterations did not show significant differences among the groups. It seems that platelet concentrates prepared from female donors show oxidative stress earlier than those from male donors. It is suggested that these products be given priority for transfusion to prevent further deterioration of the quality of platelet concentrates during storage.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TMPRSS2-coagulation nexus: a novel molecular link revealed by pairwise correlation analysis following AstraZeneca (ChAdOx1 nCoV-19) vaccination in a Nigerian cohort.","authors":"Erens Spiff Ekprikpo, Zaccheaus Awortu Jeremiah, Stella Urekweru Ken-Ezihuo, Beauty Eruchi Echonwere-Uwikor","doi":"10.1097/MBC.0000000000001467","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001467","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the pairwise molecular-haematological and coagulation correlations, specifically evaluating the relationship between TMPRSS2 gene expression and coagulation profiles, following AstraZeneca (ChAdOx1 nCoV-19) vaccination within an African population.</p><p><strong>Methods: </strong>In this case-control study, 102 adults (51 vaccinated with AstraZeneca ≥6 months prior, 51 unvaccinated controls) aged 18-65 years in Port Harcourt, Nigeria, were evaluated. Full blood count (Sysmex XN-1000), PT/aPTT (Erba Mannheim), RNA concentration, and qRT-PCR for ACE2/TMPRSS2 (normalized to GAPDH) were performed. Pearson correlations and t-tests were conducted (SPSS v26, P < 0.05).</p><p><strong>Results: </strong>The AstraZeneca-vaccinated group demonstrated a statistically significant prolongation of mean aPTT compared to unvaccinated controls (34.233 ± 0.653 s vs. 28.196 ± 0.657 s, P < 0.0001), with both group means falling within the laboratory reference interval (20-40 s). A statistically significant inverse correlation was observed between TMPRSS2 cycle threshold (CT) values and activated partial thromboplastin time (aPTT) among vaccinated participants (r = -0.325, P = 0.0202), whereas no corresponding association was detected in unvaccinated controls. Because CT values are inversely proportional to transcript abundance, this indicates that higher relative expression of TMPRSS2 (lower CT values) correlates with a progressively longer aPTT baseline. No participant reported severe thrombotic or haemorrhagic complications.</p><p><strong>Conclusion: </strong>This secondary analysis identified a statistically significant inverse correlation between TMPRSS2 CT values and aPTT among AstraZeneca-vaccinated individuals. The baseline parameters confirm that this variation occurs within physiological normal boundaries at least 6 months postvaccination, suggesting a potential long-term molecular-haemostatic homeostatic adaptation rather than a transient acute-phase prothrombotic response.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of antiphospholipid antibody testing and its impact on diagnostic yield and clinical outcomes: a multicentre cohort study.","authors":"Rashmi Natarajan, Parul Shrestha, Kim Elliott, Prasanna Partha Sarathy","doi":"10.1097/MBC.0000000000001466","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001466","url":null,"abstract":"<p><p>Antiphospholipid syndrome (APS) is an uncommon but important cause of thrombosis and pregnancy morbidity. Despite guidelines, antiphospholipid antibody (aPL) testing is frequently performed outside specialist settings, potentially reducing diagnostic yield and leading to unnecessary downstream investigations. We evaluated real-world aPL testing practices, diagnostic yield, and clinical outcomes. We conducted a retrospective cohort study across three acute hospitals, two satellite sites and 63 general practices between February and June 2024. Adults undergoing aPL testing (anticardiolipin, β2-glycoprotein-I or lupus anticoagulant) were identified from electronic pathology records. Appropriateness, completeness, results and downstream clinical outcomes were assessed against BSH/EULAR guidance and the documented clinical context. Among 691 patients tested (mean age 51.3 years; 67% women), only 34% requests were considered appropriate, and complete panels were requested in 26%. APS was confirmed in 14 patients (2%). Appropriate requests were associated with higher rates of positive results [risk ratio (RR) 2.39], APS diagnosis (RR 27.0) and management changes (RR 21.4) (all P < 0.001). Haematology, Obstetrics and Rheumatology demonstrated the highest rates of appropriate testing. aPL testing is frequently performed outside recommended clinical indications, resulting in low overall diagnostic yield. Appropriate testing is associated with improved diagnostic accuracy and clinically meaningful changes in patient management, supporting the implementation of targeted diagnostic stewardship interventions.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics, risk factors, and outcomes of pediatric thrombosis: a prospective single-center study.","authors":"Eman M Fahmy, Haidy A Youssef, Alzahraa A A Sharaf, Yasmein K A Abozaid, Eman H Salama, Mohamed A Kassem","doi":"10.1097/MBC.0000000000001464","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001464","url":null,"abstract":"<p><p>The incidence of pediatric thrombosis is increasing due to multiple causes and risk factors, including genetic and acquired factors. This study aimed to evaluate clinical characteristics, risk factors, genetic mutations, and clinical outcomes of children with thrombosis. This prospective observational study included 40 children with thrombotic events. Detailed demographic, clinical, laboratory, and imaging data, as well as clinical outcomes, were collected. Thrombophilia gene testing included MTHFR C677T and A1298C, Factor XIII V34L, and factor V Leiden mutations. Statistical analyses included univariate comparisons and multivariate logistic regression to identify predictors of poor outcomes. Twenty percentage of the study population had genetic thrombophilia, while 80% had acquired risk factors. Acquired risk factors mainly included hematological (22.5%) and cardiac disorders (20%). Venous thrombosis was the most common site (80%), followed by arterial (10%) and cardiac (10%) thrombi. MTHFR C677T and factor XIII V34L mutations were detected with genetic thrombophilia only (P < 0.01), while factor V Leiden was present in both groups (P = 0.11). Overall, 67.5% of patients improved, 20% died, and 12.5% developed permanent disabilities. Multivariate analysis identified thrombocytopenia as an independent predictor of poor outcomes [odds ratio (OR) 18.44; 95% CI: 1.76-192.49; P = 0.02]. Positive blood cultures were associated with a fourfold increased risk of adverse outcomes (OR 4.0; 95% CI: 0.75-21.23; P = 0.1). Pediatric thrombosis was predominantly caused by acquired risk factors, though genetic mutations were significantly evident in this study. Screening and early diagnosis are essential for high-risk profiles. Identifying and managing sepsis and thrombocytopenia are critical to improving outcomes.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful systemic fibrinolysis in pulmonary embolism with a thrombus-in-transit.","authors":"Silvia Ivanova, Irfan Irfan, Maria Radkova, Kristina Stoyanova, Kiril Karamfiloff","doi":"10.1097/MBC.0000000000001468","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001468","url":null,"abstract":"<p><p>Right heart thrombus-in-transit with acute pulmonary embolism (PE) is a rare but potentially lethal clinical finding. Optimal management remains controversial, particularly when major contraindications or risk factors coexist. We present a 72-year-old male admitted to the emergency room with leading diagnosis acute coronary syndrome who was later diagnosed with acute PE and a massive, mobile right heart thrombus along with a concomitant ascending aortic aneurysm. Due to high surgical risk, systemic fibrinolysis was performed under close monitoring. Follow-up echocardiography demonstrated complete resolution of the intracardiac thrombus, rapid right ventricular recovery, and an intact thoracic aorta. This case highlights the importance of echocardiography in initial evaluation of patients with acute cardiovascular symptoms and also systemic thrombolysis as a viable, life-saving strategy for right heart thrombosis even in complex clinical scenarios.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}